InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.480 -0.16 (-9.76%)+
Announcement
Release
18 Sep 2025 9:02AM
Price at Release
$1.640
Full Release
download
Summary
OncoSil Medical Limited announced positive preliminary results from the PANCOSIL Phase 1-2 Study, which is the first trial globally to administer OncoSil™ via CT-guided percutaneous injection for treating locally advanced pancreatic cancer. The study demonstrated a 90% technical success rate and observed no procedure-related mortality, though 10% of patients experienced Grade 3 serious adverse device effects. Efficacy signals were noted, with a median overall survival of 20.6 months, exceeding typical survival rates for this cancer type. The company aims to seek additional regulatory approvals in the second half of FY26, focusing on expanding its treatment reach through collaboration with interventional radiologists. Ultimately, these efforts aim to increase the adoption of OncoSil™ therapy in clinical practice.
Key Points
  • PANCOSIL study shows CT-guided percutaneous administration of OncoSil™ is safe and feasible.
  • 90% technical success rate achieved.
  • No procedure-related mortality observed.
  • 10% of patients experienced Grade 3 serious adverse device effects.
  • Median overall survival of 20.6 months, better than typical 13 months for LAPC.
  • Company targeting further regulatory approvals in the second half of FY26.
  • OncoSil expanding collaboration with interventional radiologists.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.